Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS

Lena Stockhoff, Theresa Muellner‐Bucsics, Antoaneta A. Markova, Marie Schultalbers, Simone A. Keimburg, Tammo L. Tergast, Jan B. Hinrichs, Nicolas Simon, Svetlana Gerbel, Michael P. Manns, Mattias Mandorfer, Markus Cornberg, Bernhard C. Meyer, Heiner Wedemeyer, Thomas Reiberger, Benjamin Maasoumy – 27 September 2021 – Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment for portal hypertension‐related complications. However, careful selection of patients is crucial.

The Prediction of In‐Hospital Mortality in Decompensated Cirrhosis with Acute‐on‐Chronic Liver Failure

Florence Wong, K. Rajender Reddy, Puneeta Tandon, Jennifer C. Lai, Nishita Jagarlamudi, Vanessa Weir, Beverley Kok, Sylvia Kalainy, Yanin T. Srisengfa, Somaya Albhaisi, Bradley Reuter, Chathur Acharya, Jawaid Shaw, Leroy R. Thacker, Jasmohan S. Bajaj – 25 September 2021 – Acute‐on‐chronic liver failure (ACLF) is a condition in cirrhosis associated with organ failure (OF) and high short‐term mortality.

Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allografts and Nonalcoholic Steatohepatitis

Peter J. Altshuler, Hien Dang, Adam M. Frank, Ashesh P. Shah, Jaime Glorioso, Tingting Zhan, Arturo Rios Diaz, Osama Shaheen, Carlo B. Ramirez, Warren R. Maley, Adam S. Bodzin – 25 September 2021 – The increasing prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) affects both recipient and donor populations in liver transplantation. Presently, it is unclear whether transplantation of macrosteatotic allografts is affected by the metabolic milieu of liver transplant recipients.

Seroconversion After Coronavirus Disease 2019 Vaccination in Patients Awaiting Liver Transplantation: Fact or Fancy?

Alberto Calleri, Margherita Saracco, Fabrizia Pittaluga, Rossana Cavallo, Renato Romagnoli, Silvia Martini – 25 September 2021 – Chronic liver disease increased the risk of severe coronavirus disease 2019 (COVID‐19). Trials to assess efficacy/safety of COVID‐19 vaccines in liver disease are underway. We evaluated the humoral immune response and safety of anti–COVID‐19 vaccination among patients waiting liver transplantation (LT). We enrolled all pre‐LT adults who completed anti‐COVID‐19 vaccination between January 2021‐August 2021 as study group.

Subscribe to